Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7902]

ASCO 2019: Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung cancer

ASCO 2019: Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung...

Interaction with stromal cells influences tumour growth and metastasis in pancreatic cancer

Interaction with stromal cells influences tumour growth and metastasis in pancreatic cancer

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer

ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer

$FDA approves addition of survival data to gilteritinib label for refractory AML with a FLT3 mutation$

FDA approves addition of survival data to gilteritinib label for refractory AML with a FLT3 mutation

Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients

Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic...

Study reveals structure of a 'master switch' controlling cell division

Study reveals structure of a 'master switch' controlling cell division

Steroids can reduce lung cancer risk in COPD patients

Steroids can reduce lung cancer risk in COPD patients

FDA approves ramucirumab for hepatocellular carcinoma

FDA approves ramucirumab for hepatocellular carcinoma

Newly discovered hybrid molecules could serve as a novel category of anti-cancer agent

Newly discovered hybrid molecules could serve as a novel category of anti-cancer agent

More from ecancer